Article Versions Notes

Koseki T, Teramachi M, Koga M, Ko MSH, Amano T, Yu H, Amano M, Leyder E, Badiola M, Ray P, et al. A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2. Vaccines. 2023; 11(12):1767. https://doi.org/10.3390/vaccines11121767

Koseki, Takenao, Mayumi Teramachi, Minako Koga, Minoru S. H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, and et al. 2023. "A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2" Vaccines 11, no. 12: 1767. https://doi.org/10.3390/vaccines11121767

Koseki, T., Teramachi, M., Koga, M., Ko, M. S. H., Amano, T., Yu, H., Amano, M., Leyder, E., Badiola, M., Ray, P., Kim, J., Ko, A. C., Achour, A., Weng, N.-p., Imai, T., Yoshida, H., Taniuchi, S., Shintani, A., Fujigaki, H., ... Doi, Y. (2023). A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2. Vaccines, 11(12), 1767. https://doi.org/10.3390/vaccines11121767